Summary
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
MaxCyte Q1 Earnings Call Highlights
MaxCyte NASDAQ: MXCT reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core revenue, while milestone revenue from a registrational-stage program helped offset part of the decline.
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.
MaxCyte, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BG Bart Gancher Intech Investment Management LLC | 27,027 | $73,252.96 | $39,459.42 | -$33,793.54 | -46.13% |
 Joseph Castro Nuveen LLC | 218,497 | $594,092.26 | $317,913.13 | -$276,179.13 | -46.49% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 32 | $22.48 | $45.92 | $23.44 | 104.27% |
| DH Dinan Hu R Squared Ltd | 12,060 | $8,472 | $17,487 | $9,015 | 106.41% |
| PK Parth Karia Capricorn Fund Managers Ltd. | 8.2M | $5.76M | $11.73M | $5.97M | 103.56% |
MaxCyte, Inc. (MXCT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has MaxCyte, Inc. ever had a stock split?
MaxCyte, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Maher Masoud CEO | NASDAQ (NGS) Exchange | 57777K106 CUSIP |
| US Country | 91 Employees | - Last Dividend | - Last Split | 30 Jul 2021 IPO Date |
Overview
MaxCyte, Inc. is a pioneering life sciences company deeply involved in the discovery, development, and commercialization of advanced cell therapies both within the United States and internationally. Since its inception in 1998, MaxCyte has positioned itself at the forefront of cell therapy technologies, offering innovative solutions that propel the research and development of next-generation treatments. With its headquarters in Rockville, Maryland, the company stands as a key player in the life sciences field, providing essential technology and products to pharmaceutical and biotechnology companies, as well as developers of cell therapies. MaxCyte’s contributions span from drug discovery and development to bio-manufacturing, aimed at enhancing the efficacy and application of cell-based treatments across various therapeutic areas.
Products and Services
-
ExPERT ATx:
This static electroporation instrument is designed for small to medium scale transfection, making it an ideal solution for researchers and clinicians working on the development of cell therapies. The ATx model facilitates the precise and efficient delivery of genetic material into cells, a critical step in many cell therapy protocols.
-
ExPERT STx:
A flow electroporation system tailored for protein production and drug development processes. It also plays a vital role in the expression of therapeutic targets for cell-based assays. The STx model is recognized for its capability to enhance the productivity and reliability of these crucial early-stage processes.
-
ExPERT GTx:
This model specifically caters to the requirements of large scale transfection in therapeutic applications, employing flow electroporation technology to ensure high efficiency and scalability. The GTx is integral for the production of cell therapies at a scale necessary for clinical trials and commercialization.
-
ExPERT VLx:
For very large volume cell-engineering, the VLx provides an unparalleled solution. This model of MaxCyte's electroporation technology supports the highest throughput requirements, enabling the processing of vast quantities of cells with consistent results, pivotal for the mass production of cell-based therapies.
In addition to these innovative instruments, MaxCyte offers disposable processing assemblies (PAs), which are critical for the practical application of electroporation in cell processing. These PAs, along with necessary accessories such as electroporation buffer solution and software protocols, are designed to ensure the optimal performance of MaxCyte’s electroporation technology. The company's business model includes licensing and selling its groundbreaking instruments and technology, alongside the sale of consumables to a diverse clientele including cell therapy developers, pharmaceutical and biotechnology companies focused on drug discovery, development, and bio-manufacturing.
